Alnylam Pharmaceuticals (ALNY) Is Up 5.4% What’s Changed After Five Year Drug Data
Alnylam Pharmaceuticals (ALNY) Is Up 5.4% What’s Changed After Five Year Drug Data Simply Wall St
Covered in this story
What has happened since
- Alnylam Pharmaceuticals is up 5.0% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Alnylam Pharmaceuticals
- Truist Securities: at $161 · target $225 by Nov 2027 via GuruFocus
- Canaccord Genuity: at $158 · target $323 by Nov 2027 · Buy via GuruFocus
- Bernstein: at $165 · target $199 by Oct 2027 via GuruFocus
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ALNY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alnylam Pharmaceuticals →Dalsna Finance is currently tracking 36 stories mentioning Alnylam Pharmaceuticals, the earliest published 6 May 2017.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.